Welcome to our dedicated page for Icecure Medical Ltd. SEC filings (Ticker: ICCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IceCure Medical Ltd. (Nasdaq: ICCM) is a foreign private issuer that files reports with the U.S. Securities and Exchange Commission (SEC) in connection with its liquid-nitrogen-based cryoablation systems for tumor destruction. On this page, you can review IceCure’s SEC filings, including current reports on Form 6-K that furnish press releases about regulatory milestones, clinical data, commercial progress, and corporate actions.
IceCure’s Form 6-K filings often incorporate press releases by reference into its registration statements on Form F-3 and Form S-8. These filings cover topics such as U.S. Food and Drug Administration (FDA) marketing authorization for the ProSense® Cryoablation System in low-risk breast cancer for women aged 70 and above, regulatory approvals for ProSense® in Switzerland and other markets, notices of patent allowance for technologies like cryogen flow control related to the next-generation XSense™ system, and financial and operational results for specified reporting periods.
Filings also document corporate developments, including changes in management roles and Nasdaq notifications regarding minimum bid price compliance. By reviewing these documents, investors can see how IceCure describes its minimally invasive cryoablation technology, its primary focus areas in breast, kidney, bone, and lung cancer, and the regulatory and commercial steps it reports taking to expand use of ProSense® and XSense™.
Stock Titan’s SEC filings page presents IceCure’s submissions as they are made available on EDGAR and enhances accessibility with AI-powered summaries. These summaries are designed to highlight key points from lengthy documents, such as the nature of a regulatory authorization, the scope of a patent allowance, or the main elements of a financial update. Users can quickly identify filings related to clinical milestones, regulatory approvals, capital markets activity, and other material events disclosed by IceCure Medical Ltd.
IceCure Medical Ltd. reports that the U.S. FDA has granted marketing authorization for its ProSense® cryoablation system to treat low-risk breast cancer in women aged 70 and above. The company furnished two press releases on this authorization, highlighting it as a significant development in providing women with breast cancer a minimally invasive care option. Portions of these press releases are also incorporated by reference into several of IceCure's existing Form F-3 and Form S-8 registration statements.
IceCure Medical Ltd. filed a Form 6-K to furnish a press release dated September 30, 2025 about its ProSense® system’s presence at the European Society of Breast Imaging Congress 2025. The release highlights "unlocking de-escalation of care in breast cancer" and positive results from five independent studies. Most of the press release (excluding its second paragraph) is incorporated by reference into IceCure’s existing Form F-3 and Form S-8 registration statements, meaning that disclosure becomes part of those registration documents going forward unless later superseded.
IceCure Medical Ltd. submitted a Form 6-K reporting that it issued a press release on September 22, 2025 titled “IceCure’s ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented.” The press release, excluding its second paragraph, is attached as an exhibit and describes positive clinical results for the company’s ProSense cryoablation technology from four independent studies presented at the CIRSE 2025 annual meeting. The company is also incorporating this press release by reference into several of its existing Form F-3 and Form S-8 registration statements.
IceCure Medical Ltd. filed a Form 6-K to furnish a press release announcing that it was granted a notice of allowance for a U.S. patent covering its next generation XSense™ cryoprobes. The press release, dated September 18, 2025, is attached as Exhibit 99.1.
The filing also states that the first and third paragraphs of the press release, along with its “Forward Looking Statements” section, are incorporated by reference into IceCure’s existing registration statements on Form F-3 and Form S-8 in the United States, making this information part of those registration documents from the date of this submission.
IceCure Medical Ltd. furnished a report noting it has received regulatory approval in Israel for its next-generation XSense™ cryoablation system for breast cancer and other indications, as described in a press release dated September 15, 2025. The press release is included as Exhibit 99.1 to this report.
The first, second and fifth paragraphs of that press release, along with its forward-looking statements section, are incorporated by reference into IceCure’s existing registration statements on Form F-3 and Form S-8, so they become part of those offering documents from the date of this submission.
IceCure Medical Ltd. held a Special General Meeting of Shareholders on September 1, 2025, where a quorum was present and voting took place. Shareholders approved all agenda items that had been described in the company’s proxy statement for the meeting, which had been furnished to the SEC on August 1, 2025. The report states that this Form 6-K is incorporated by reference into IceCure Medical’s existing registration statements on Form F-3 and Form S-8, meaning it becomes part of those offering documents from the date of submission.
IceCure Medical Ltd. submitted a Form 6-K to furnish a new press release dated September 4, 2025. The release, titled “IceCure’s ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy,” highlights results related to use of the company’s ProSense® system for abdominal wall endometriosis pain and describes high procedural efficacy.
Except for its fourth paragraph, the press release is incorporated by reference into IceCure’s existing shelf and equity compensation registration statements on Form F-3 and Form S-8, making the clinical and procedural information part of those U.S. securities offerings documentation going forward, unless later filings replace it.
IceCure Medical Ltd. convened its Annual and Special General Meeting of Shareholders on August 20, 2025. A quorum was present, and shareholders approved all agenda items that had been described in the company’s proxy statement furnished to the SEC on July 16, 2025. The report notes that this information is incorporated by reference into IceCure Medical’s existing registration statements on Form F-3 and Form S-8, meaning those registration statements now include the outcomes of this meeting as part of their disclosure record.
IceCure Medical Ltd. filed a Form 6-K as a foreign private issuer, providing investors with a package of information on its performance for the first half of 2025. The report furnishes unaudited interim condensed consolidated financial statements as of and for the six months ended June 30, 2025.
It also includes management’s discussion and analysis of financial condition and results of operations for the same period, plus a press release titled “IceCure Reports Financial & Operational Results for the First Half of 2025.” These materials are incorporated by reference into existing Form F-3 and Form S-8 registration statements.